)
Aurobindo Pharma has received the final approval from the US Food and Drug Administration to manufacture and market Atracurium Besylate injection in single and multi-dose vials in the US market.
The drug is a bio-equivalent and therapeutically equivalent to the reference listed drug product Atracurium Besylate Injections of Eurohealth International Sarl, the company said on Thursday.
The drug product is used as an adjunct to general anesthesia and to provide skeletal muscle relaxation during the surgery or mechanical ventilation, according to the company.
